Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
4(57.1%)
Phase 1
3(42.9%)
7Total
Phase 2(4)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06961344Phase 2Enrolling By Invitation

An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

Role: lead

NCT06402123Phase 2Active Not Recruiting

A Phase 2b Study of Zagociguat in Patients With MELAS

Role: lead

NCT04798989Phase 2Terminated

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

Role: lead

NCT04475549Phase 2Terminated

Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

Role: lead

NCT03856827Phase 1Completed

A Study of IW-6463 in Healthy Volunteers

Role: lead

NCT04240158Phase 1Terminated

IW-6463 Safety Study in Healthy Elderly Subjects

Role: lead

NCT04972227Phase 1Completed

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

Role: lead

All 7 trials loaded